Study to Assess How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult Participants
← catalyst calendarNCT07680686 · readout ≤ 73 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Basic science
Enrollment
52estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-14 | actual | When the study began enrolling |
| Primary completion | Oct 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteer
Interventions
- Drug: Ubrogepant
- Drug: Ubrogepant
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants Experiencing Adverse Events
measured Up to approximately 33 days
Area under the plasma concentration-time curve from time 0 until the last measurable concentration (AUCt) of Ubrogepant
measured Up to approximately 3 days
AUC From Time 0 to the Time Infinity (AUCinf) of Ubrogepant
measured Up to approximately 3 days
Maximum Observed Plasma Concentration (Cmax) of Ubrogepant
measured Up to approximately 3 days
Time lag between dosing and drug to appear in systemic circulation following extravascular administration (Tlag) of Ubrogepant
measured Up to approximately 3 days
Time to maximum observed plasma concentration (Tmax) of Ubrogepant
measured Up to approximately 3 days
Apparent terminal phase elimination constant (λz) of Ubrogepant
measured Up to approximately 3 days
Terminal phase elimination half-life (t1/2) of Ubrogepant
measured Up to approximately 3 days
Apparent total body clearance of drug from plasma after extravascular administration (CL/F) of Ubrogepant
measured Up to approximately 3 days
Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F) of Ubrogepant
measured Up to approximately 3 days
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed